

## Details of the Potential Loan



U.S. Government formalizes interest to provide a loan to launch **Kodak Pharmaceuticals** in the amount of **\$765M**

The loan application is currently on hold. If finalized, the company would produce **generic pharmaceutical components**, strengthening U.S. supply chains and creating American jobs


## Why it Matters?

The US consumes

**40%**

of the world's active pharmaceutical ingredients (APIs)

but the majority of these APIs come from India and China



Kodak Pharmaceuticals would have the ability to produce up to

**25%**

of US pharmaceutical components for generic usage\*

\*APIs are used to produce generic pharmaceuticals. Kodak Pharmaceuticals would produce APIs for generic usage that are neither antibacterial nor biologics

The deal would stimulate the **Rochester, NY** economy with **300 direct** and **1,200 indirect jobs**

## Why Kodak?

- **100+ years** of experience in advanced materials, chemicals, and chemical manufacturing, with existing team of scientists, chemists, engineers, technicians, and commercialization managers
- Capacity to make up to **30 different APIs** to be used in formulating generic drugs
- Ability to immediately store and stockpile “**Key Starting Materials**” (KSM) for the current pandemic and future health crisis situations, as well as produce unregulated KSMs for Essential Medicines in Shortage utilizing existing facilities
- Primary location at Rochester, NY’s **Eastman Business Park**, an existing 1,200 acre industrial site with the infrastructure to support these manufacturing needs